CN1192910A - Oral liquor for treatment of lung cancer and preparation method therefor - Google Patents
Oral liquor for treatment of lung cancer and preparation method therefor Download PDFInfo
- Publication number
- CN1192910A CN1192910A CN97101000A CN97101000A CN1192910A CN 1192910 A CN1192910 A CN 1192910A CN 97101000 A CN97101000 A CN 97101000A CN 97101000 A CN97101000 A CN 97101000A CN 1192910 A CN1192910 A CN 1192910A
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- treatment
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a pure Chinese medicinal oral liquor for curing pulmonary carcinoma and its preparation method. Said invented oral liquor is made up by using 14 kinds of Chinese medicinal materials, adopting modern scientific technological process, combining traditional preparation experience and extracting their effective components, so that it provides an ideal anti-cancer medicine with the functions of promoting blood circulation by removing blood stasis, clearing heat away and toxic material, removing obstruction and relieving pain, removing the nectoric tissue and promoting granulation and strengthening immunity and with obvious therapeutic effect for patients with intermediate and late pulmonary carcinoma.
Description
The invention belongs to Chinese medicine preparation, a kind of oral liquid that is used for the treatment of pulmonary carcinoma and preparation method thereof.
At present, the treatment method for cancer is a lot of both at home and abroad, the main means such as operation, radiotherapy or chemotherapy that adopt, but put, in the process of chemotherapy, the healthy cell of human body and immune system also are subjected to injury in various degree simultaneously, this is difficult to bear for a cancer patient that has a delicate constitution, especially to one lost surgical engine can in, end-stage patients are willing and yet unable to help especially, expect earnestly a kind of enhancing human body immunity power can be arranged, cancer therapy drug comes out early safely and effectively.
The objective of the invention is to propose a kind of be in, be not suitable for operating late period or carry out the lung cancer patient of radiotherapy, chemotherapy, a kind of relief of symptoms be provided, prolong life, safe and reliable, taking convenience, curative effect be obvious, total effective rate can reach the desirable curing cancer drug more than 90%, treatment pulmonary carcinoma oral liquid.
Major technique content of the present invention is that this treatment pulmonary carcinoma oral liquid prescription and weight proportion are: Herba Agrimoniae 20～25%, Herba Hedyotidis Diffusae 10～15%, Herba Scutellariae Barbatae 10～12%, Radix Scutellariae 6～8%, the Radix Astragali 6～8%, Radix Sophorae Flavescentis 5～6%, Radix Salviae Miltiorrhizae 5～6.5%, Herba Taraxaci 4～5%, Radix Adenophorae (Radix Glehniae) 4.5～5.5%, Radix Ophiopogonis 4.5～5.5%, the Rhizoma Atractylodis Macrocephalae 5～6%, Herba Lobeliae Chinensis 4～5%, Radix Glycyrrhizae 3～3.5%, Fructus Ligustri Lucidi 3～3.5%.
The preparation method of described pulmonary carcinoma oral liquid is with Herba Agrimoniae, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Radix Scutellariae, the Radix Astragali, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae, Herba Taraxaci, Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Herba Lobeliae Chinensis, Radix Glycyrrhizae, 14 flavor Chinese medicines such as Fructus Ligustri Lucidi add water to the medicine submergence, decoct secondary, decocted 2～2.5 hours for the first time, decocted 1～1.5 hour for the second time, filter the back merging filtrate respectively, concentrate, left standstill 24 hours, get its supernatant, add the sucrose reheat dissolving of medicinal liquid total amount 20～30%, the cooling back adds distilled water 2 times to prepared slices of Chinese crude drugs total amount, stirs evenly, liquid after the filtration is treatment pulmonary carcinoma oral liquid, and packing gets final product.
The present invention is in excavating motherland's pools of traditional Chinese medicine, in conjunction with clinical experience for many years, use modern science and technology Chinese medicines such as Chinese medicine Herba Agrimoniae, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Radix Sophorae Flavescentis, Radix Salviae Miltiorrhizae, Radix Adenophorae (Radix Glehniae), the Radix Astragali, Radix Scutellariae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Herba Taraxaci, Radix Glycyrrhizae, Fructus Ligustri Lucidi, Herba Lobeliae Chinensis are processed into oral liquid through screening, the process of preparing Chinese medicine.Herba Agrimoniae has astringing to arrest bleeding; Radix Astragali energy granulation promoting poison holding, the Radix Salviae Miltiorrhizae promoting blood circulation to remove obstruction in the collateral; The Radix Glycyrrhizae QI invigorating and in; Radix Ophiopogonis, Radix Adenophorae (Radix Glehniae) energy moistening the lung and resolving phlegm, nourishing YIN and clearing away heat; Herba Lobeliae Chinensis, Herba Scutellariae Barbatae, Herba Taraxaci, Radix Scutellariae, Radix Sophorae Flavescentis have heat-clearing and toxic substances removing, reducing swelling and alleviating pain, effects such as blood circulation promoting and blood stasis dispelling; Fructus Ligustri Lucidi, Rhizoma Atractylodis Macrocephalae energy invigorating QI to consolidate the body surface resistance, enhancing human body immunity function, right supporting anticancer; Herba Hedyotidis Diffusae has inhibitory action to cancer and can form by enhancing antibody, improves leukocytic phagocytic activity.More than each medicine compatibility make oral liquid.Therefore this medical instrument blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, removing obstruction for relieving pain arranged, remove the rotten and let fresh grow, immune cell activated, improve immunologic function, promote the nutrition rehabilitation of the The Nomenclature Composition and Structure of Complexes of tissue and cell, the enhancing body resistance against diseases, kill the carcinoma cell, the tumor body is dwindled, alleviate and alleviate clinical symptoms, improve patient's life quality, thereby prolong patient's life.
Embodiments of the invention:
Get Herba Agrimoniae 200g, Herba Hedyotidis Diffusae 130g, Herba Scutellariae Barbatae 120g, Radix Scutellariae 80g, Radix Astragali 80g, Radix Sophorae Flavescentis 50g, Radix Salviae Miltiorrhizae 30g, Herba Taraxaci 45g, Radix Adenophorae (Radix Glehniae) 45g, Radix Ophiopogonis 50g, Rhizoma Atractylodis Macrocephalae 50g, Herba Lobeliae Chinensis 40g, Radix Glycyrrhizae 30g, Fructus Ligustri Lucidi 30g, decoct with water secondary, it is 2 hours for the first time, it is 1 hour for the second time, after filtering respectively, merging filtrate, after concentrating, leave standstill and got supernatant adding 500g sucrose in 24 hours, heating for dissolving, cooling back adding distil water stirs evenly filtration to 2000ml, and liquid subpackage is got final product.
Instructions of taking: every day three times, each 40ml (heating before the clothes) taking medicine before meal is used.
The present invention is without any side effects through zoopery and clinical use, and effect is remarkable.From January nineteen ninety-five～1997 year January to 192 examples in, the short term effect of advanced lung cancer is obvious.Clinical sign and clinical symptom remission rate are 87.5%, and the focus minification is 45.4%, and 1 year person of survival period is 94.1%, and be more obvious to improving patient's quality of life and prolonging life cycle.Through clinical observation, definite diagnosis before the treatment is a foundation with lonizing radiation (X line, CT) endoscope, surgery Pathology (human cytology) check etc., to this group patient's treatment, its drug dose is 40ml, day clothes three times, ante cibum is oral, continuous use was a course of treatment in one month, had a rest a week, continued course of treatment of medication then, be a total course of treatment three courses of treatment, also can take throughout one's life.Observation before and after the patient treatment, write up symptom, sign change, binding of pathological is learned and checked simultaneously: actinology (X line, CT), conventional urine, blood sample test, liver, renal function check etc. finish the back and follow up a case by regular visits to once every half a year as foundation total course of treatment.
Observe as follows with reference to " pulmonary carcinoma efficacy assessment standard " to 192 routine medium and advanced lung cancer short term effects:
Produce effects: partly alleviating (PR) focus dwindles＞and 50%, clinical symptoms is obviously improved.
Effectively: slightly alleviating (MR) focus dwindles＜and 50%, clinical symptoms makes moderate progress.
Invalid: do not have alleviating (PD) focus does not have and dwindles or increase to some extent, and clinical symptoms increases the weight of.
The male is 129 examples in 192 examples, women's 63 examples, and men and women's ratio is 2: 1.Age reckling 16 years old, the oldest person 79 years old, the mean age is 56.2 years old.50-60 year, age group amounted to 69 examples, and accounting for this group 35.9% is age bracket occurred frequently.Age bracket amounted to 39 examples and accounted for this group 21% 40-50 year.Centre type 149 examples, peripheral type 43 examples.Focus is positioned in the right lung, and the person is 123 examples, and left lung person is 68 examples, and two lung persons are 1 example only.Above-mentioned case is medium and advanced lung cancer (all have in various degree and shift).
Sign and observation of symptoms: this organize 192 routine patients take this Drug therapy after total course of treatment observed result be that cough, uncomfortable, uncomfortable in chest, chest pain etc. all have clear improvement, even disappearance.Expectoration, sputum mixed with blood, heart beating are breathed hard, slight fever also has alleviation, so the alleviation degree of sign and symptom is 87.5%, see table 1 for details.
Sign and symptom variation before and after the treatment of table 1 192 side medium and advanced lung cancers
| Sign, symptom | The example number | Obviously alleviate | The slight alleviation | Invalid | Remission rate % |
| Cough | ????192 | ????65 | ????107 | ????20 | ????89.6 |
| Expectoration | ????45 | ????30 | ????26 | ????9 | ????86.2 |
| Become thin | ????189 | ????25 | ????139 | ????25 | ????86.8 |
| Anorexia | ????179 | ????32 | ????132 | ????15 | ????91.6 |
| Hemoptysis expectorant | ????63 | ????15 | ????36 | ????12 | ????80.9 |
| Chest pain | ????190 | ????35 | ????139 | ????16 | ????91.6 |
| Uncomfortable in chest | ????177 | ????39 | ????122 | ????16 | ????90.0 |
| Slight fever | ????93 | ????39 | ????40 | ????14 | ????84.8 |
| The heart beating of breathing hard | ????105 | ????15 | ????76 | ????14 | ????86.7 |
| Weak | ????182 | ????39 | ????119 | ????24 | ????86.8 |
Annotate: patient one people is simultaneously with multiple sign symptom, classified counting during statistics during statistics.
Result before and after lonizing radiation (X line, CT) contrast is taken medicine, after 192 routine medium and advanced lung cancer patients use the total end course of treatment of this medicine, observing the preceding pulmonary lesions minification of treatment is 45.4%., pulmonary lesions dwindles＞50% (comprising 50%) above person be 7.2%, pulmonary lesions dwindles＜and 50% be 351%, be considerable so use behind this medicine to the pulmonary lesions curative effect.See table 2 for details.
Table 2 medium and advanced lung cancer treatment back pulmonary lesions dwindles observation
| Typing | The example number | Pulmonary lesions dwindles degree | |||
| ??＞1/2 | ??＜1/2 | No change | Minification % | ||
| Centre type | ????149 | ????11 | ????48 | ????90 | ????39.6 |
| Peripheral type | ????43 | ????5 | ????17 | ????21 | ????51.2 |
| Add up to | ????192 | ????16 | ????65 | ????111 | ????45.4 |
Annotate: have an example only to make case statistics for the bilateral person in the statistics, this example is a centre type.
Quality of life observes: after this group patient used this Drug therapy, variation had taken place in integral body, and especially the raising of patient quality of life is more considerable, to patient live bring happy.The life person that fully not can take care of oneself is that 15 examples account for this group 7.8% before the treatment, can not self-care person be 119 examples fully, accounts for this group 62%; Life person's 114 examples that fully not can take care of oneself account for this group 59.4% after this Drug therapy, rise 51.6%, and life fully self-care person be 21 examples, account for this group 10.9%, decline 51.1% sees table 3 for details.
The life quality of observing the patient is very important, but observes the valuable index that also be this curative effect of medication of explanation its life cycle.192 routine patients are after medication, can the communication contact person totally 102, the year and a day person that now survives has 96, account among the person of following up a case by regular visits to 94.1%, the life cycle of medium and advanced lung cancer is than short, though previously all produce little effect through multiple treatment measure, and with behind this medicine, patient's the annual phase of depositing is significantly improved, so this medicine is a desirable evidence to current medium and advanced lung cancer patient.
The observation of quality of life before and after the treatment of table 3 medium and advanced lung cancer
| The treatment situation | Life is taken care of oneself fully | Life partial self-help | Can't take care of oneself at all | |||
| The example number | Percentage ratio | The example number | Percentage ratio | The example number | Percentage ratio | |
| Before the treatment | ???15 | ????7.8 | ???58 | ????30.2 | ????119 | ???62 |
| After the treatment | ???114 | ????59.4 | ???57 | ????29.7 | ????21 | ???10.9 |
Show from the observation of curative effect of this research, take this medicine medium and advanced lung cancer is had uniqueness and obvious curative effects, sign and clinical symptoms all have positive effect, its total effective rate is 87.5%, through lonizing radiation checks (X line, CT), the pulmonary lesions minification is 45.4%, and patient's fuselage state obviously improves, quality of life improves constantly, and 1 year its life cycle, the person was unexpectedly up to 94.1%.This group patient is the middle and advanced stage patient, and end-stage patients promptly can not perform the operation, and most of patient can not accept radiation and chemotherapy, so patient's life cycle is shorter, current phase patient's treatment has become difficulty to this.And can improve sings and symptoms after using this medicine, and can improve the quality of life again, prolong life cycle, most of patient's clinical symptoms all takes an evident turn for the better simultaneously, pulmonary lesions dwindles, and patient has not only treated pulmonary carcinoma after taking this medicine, and also effective in cure to other complication, complication.Because this medicine can improve patient's autoimmunity, so that this medicine and operation, radiotherapy, chemotherapy combined are used its curative effect is better.
By animal experiment and clinical observation, this medical instrument has the division that suppresses tumor cell, even killing action is arranged, thereby growth of tumor is controlled.
These medicine characteristics: nontoxic, side effect, be safer, reliable, efficient, without the anticancer good medicine of contraindication.
The curative effect of this medicine can provide the use testimonial material of related hospitals.
Claims (1)
1, a kind of oral liquid and compound method thereof for the treatment of pulmonary carcinoma, it is characterized in that this oral liquid by: Herba Agrimoniae 20～25%, Herba Hedyotidis Diffusae 10～15%, Herba Scutellariae Barbatae 10～12%, Radix Scutellariae 6～8%, the Radix Astragali 6～8%, Radix Sophorae Flavescentis 5～6%, Radix Salviae Miltiorrhizae 5～6.5%, Herba Taraxaci 4～5%, Radix Adenophorae (Radix Glehniae) 4.5～5.5%, Radix Ophiopogonis 4.5～5.5%, the Rhizoma Atractylodis Macrocephalae 5～6%, Herba Lobeliae Chinensis 4～5%, Radix Glycyrrhizae 3～3.5%, Fructus Ligustri Lucidi 3～3.5% are formed, and said ratio is weight ratio; Its outfit method is that 14 flavor Chinese medicines add water to the medicine submergence, decoct secondary.Decocted 2～2.5 hours for the first time, decocted 1～1.5 hour for the second time, filter the back merging filtrate respectively, concentrate, left standstill 24 hours, get its supernatant, the sucrose that adds amount of liquid medicine 20～30%, heating for dissolving, the cooling back adds distilled water 2 times to prepared slices of Chinese crude drugs total amount, stirs evenly the filtration packing and gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97101000A CN1055235C (en) | 1997-03-12 | 1997-03-12 | Oral liquor for treatment of lung cancer and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97101000A CN1055235C (en) | 1997-03-12 | 1997-03-12 | Oral liquor for treatment of lung cancer and preparation method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1192910A true CN1192910A (en) | 1998-09-16 |
| CN1055235C CN1055235C (en) | 2000-08-09 |
Family
ID=5165463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97101000A Expired - Fee Related CN1055235C (en) | 1997-03-12 | 1997-03-12 | Oral liquor for treatment of lung cancer and preparation method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1055235C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011559B (en) * | 2007-02-01 | 2011-06-01 | 南中兴 | Traditional Chinese medicine preparation for treating malignant tumor and its preparation method |
| CN101612251B (en) * | 2009-07-27 | 2011-08-31 | 沈信堂 | Traditional Chinese medicine for treating primary liver cancer |
| CN108355014A (en) * | 2018-05-23 | 2018-08-03 | 北京雄九医学研究院 | Anticancer traditional Chinese medicinal composition |
-
1997
- 1997-03-12 CN CN97101000A patent/CN1055235C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011559B (en) * | 2007-02-01 | 2011-06-01 | 南中兴 | Traditional Chinese medicine preparation for treating malignant tumor and its preparation method |
| CN101612251B (en) * | 2009-07-27 | 2011-08-31 | 沈信堂 | Traditional Chinese medicine for treating primary liver cancer |
| CN108355014A (en) * | 2018-05-23 | 2018-08-03 | 北京雄九医学研究院 | Anticancer traditional Chinese medicinal composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1055235C (en) | 2000-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041317B (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN100457158C (en) | Medicine for fortifying human body immune function | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN101234181B (en) | Medicament for preventing and treating leukopenia used in tumor radiotherapy and chemotherapy course | |
| CN1150928C (en) | Medicine for curing cancers and its preparation method | |
| CN1305515C (en) | Chinese medicine powder and decoction composition for treating cancers | |
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN100386106C (en) | Medicine for treating acne and its preparation | |
| CN1055235C (en) | Oral liquor for treatment of lung cancer and preparation method therefor | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN101361789A (en) | Traditional Chinese medicine formulation for treating and preventing lung impairment after tumor controlling radiotherapy | |
| CN112426448A (en) | Preparation method of health tea | |
| CN101940699B (en) | Traditional Chinese medicine for assisting in treating liver cancer | |
| CN1294961C (en) | Oral liquid for curing myocardial ischemia and process for preparing the same | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN115089663B (en) | Traditional Chinese medicine composition with qi-tonifying and body fluid-generating effects and preparation method thereof | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN1186060C (en) | Chinese medicine capsule and adhesive plaster for treating mammary cancer and its preparation method | |
| CN102580053B (en) | Traditional Chinese medicine formulation for preventing and treating cancer | |
| CN102228661B (en) | Chinese medicinal cholecystitis treatment mixture for treating chronic cholecystitis | |
| CN101396454B (en) | Traditional Chinese medicine for treating diabetic skin pruritus | |
| CN1325105C (en) | Oral liquid for clearing liver and gallbladder | |
| CN1289123C (en) | Medicine for treating late malignant tumour | |
| CN1413657A (en) | Chinese medicine capsule, pill for treating liver cancer and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |